key: cord-0748143-4g1s99a8
authors: Piazzi, Manuela; Bavelloni, Alberto; Cenni, Vittoria; Faenza, Irene; Blalock, William L.
title: Revisiting the Role of GSK3, A Modulator of Innate Immunity, in Idiopathic Inclusion Body Myositis
date: 2021-11-21
journal: Cells
DOI: 10.3390/cells10113255
sha: 839165735ccebd891c418421a8d8fb402d07d0d6
doc_id: 748143
cord_uid: 4g1s99a8

Idiopathic or sporadic inclusion body myositis (IBM) is the leading age-related (onset >50 years of age) autoimmune muscular pathology, resulting in significant debilitation in affected individuals. Once viewed as primarily a degenerative disorder, it is now evident that much like several other neuro-muscular degenerative disorders, IBM has a major autoinflammatory component resulting in chronic inflammation-induced muscle destruction. Thus, IBM is now considered primarily an inflammatory pathology. To date, there is no effective treatment for sporadic inclusion body myositis, and little is understood about the pathology at the molecular level, which would offer the best hopes of at least slowing down the degenerative process. Among the previously examined potential molecular players in IBM is glycogen synthase kinase (GSK)-3, whose role in promoting TAU phosphorylation and inclusion bodies in Alzheimer’s disease is well known. This review looks to re-examine the role of GSK3 in IBM, not strictly as a promoter of TAU and Abeta inclusions, but as a novel player in the innate immune system, discussing some of the recent roles discovered for this well-studied kinase in inflammatory-mediated pathology.

Inclusion body myositis (IBM) is a rare disorder affecting the long muscles of the arms, legs and neck, occurring in about seven individuals per million; yet, it represents one of the leading causes of muscle-related debilitation in the elderly [1] . In contrast to other autoimmune/autoinflammatory pathologies, IBM occurs prevalently in males (3:1, male:female ratio). As with Alzheimer's disease, the initial events of this pathology begin long before any overt symptoms appear, as inflammation and the degeneration of muscle tissue may initiate 10 years prior to any symptoms. While symptom onset as early as 45 years of age is not unheard of, the typical age for the onset of symptoms is over 65 [1, 2] . Affected individuals usually begin noticing difficulty in climbing stairs and an increased tendency to trip, due to foot drop and/or buckling knees, leading to frequent falls and the risk of fractures. Individuals also have extreme difficulty in rising from the seated position. These physical difficulties are accompanied by atrophy of the quadriceps, wrist and finger flexor muscles so that often advanced IBM patients are confined to a wheelchair. As the disease progresses, individuals have difficulty grasping objects and eventually may lose the ability to bend their fingers and close their hand altogether. Atrophy of the neck muscles will result in the drooping of the head and dysphagia in approximately 50% of affected individuals [1, 2] . This later often constitutes Therapy for inclusion body myositis in the past has included general immunomodulators/suppressors (glucocorticoids, azathioprine, methotrexate and cyclophosphamide), immunoglobulins and monoclonal antibody to mature B-cells (alemtuzumab) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Most of the documented responses become refractory to therapy within three Originally defined as a degenerative pathology, inclusion body myositis, like Alzheimer's disease, has recently been reclassified as an inflammatory pathology with degenerative sequalae [1, 2] . Muscle biopsies have indicated the presence of invading CD8 + cytotoxic T lymphocytes (CTL) and macrophages, with CD4 + T lymphocytes and macrophages localized to the non-necrotic muscle tissue. The presence of autoantibody to cytosolic 5 -nucleotidase 1A (5NT1A), an enzyme involved in the regulation of adenosine levels that is highly expressed in skeletal muscle, also indicates an involvement of the humoral branch of the immune system, whereby the 5NT1A-specific antibodies produced by autoreactive B lymphocytes can contribute to the immune/inflammatory destruction of the muscle tissue. In addition, an up-regulation of the major histocompatibility complex (MHC)-I molecule is observed in affected muscle tissue fibers, likely directing the CTL-mediated response in these tissues. Rimmed vacuoles with inclusions are also a characteristic feature of IBM, although they are absent in about 20% of IBM patients, nor will all the affected muscle fibers from patients with inclusions stain for these structures [1, 2] . These inclusions have been proposed to be due to an alteration in protein synthesis and processing that results in the accumulation of toxic betaamyloid (Abeta) and TAU complexes, although more than 80 proteins (including ubiquitin, HSP70, γ-tubulin, BACE 1/2, nNOS, iNOS, SOD1, IL1α/β, IL6 and GSK3, among others) have been identified and Abeta and TAU are not always present [2] [3] [4] . Not only do these complexes induce apoptotic pathways, but they have also been shown to stimulate the release of interleukin (IL)-6, an inflammatory cytokine that promotes the recruitment/activation of inflammatory macrophages and natural killer (NK) cells as part of the innate immune response, and in CD4 + T-helper and B-cell differentiation during adaptive immune responses [1, 2] . In addition, muscle biopsies from IBM patients demonstrate an increased number of cytochrome c oxidase negative fibers, indicating alterations in mitochondrial homeostasis and cellular respiration. To this end, a study by Hedberg-Oldfors et al. has recently reported that IBM muscle tissue contains mitochondrial DNA (mtDNA) rearrangements (deletions and duplications) and nucleotide variants, with the average mtDNA copy number in IBM muscle reduced by 42% [5] . This was found to result in significant complex I and complex IV deficiency in COX-deficient fibers. Such mitochondrial defects produce pleotropic effects including reduced ATP generation, enhanced ROS production and the misfolding of proteins ( Figure 1 ).

Therapy for inclusion body myositis in the past has included general immunomodulators/suppressors (glucocorticoids, azathioprine, methotrexate and cyclophosphamide), immunoglobulins and monoclonal antibody to mature B-cells (alemtuzumab) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Most of the documented responses become refractory to therapy within three months, hence physical therapy and rehabilitation has remained a highly important aspect of IBM therapy. Additional therapies to target protein misfolding (arimoclomol) and lymphocyte migration (natalizumab) are currently in trial, while partial responses have been reported to date with anakinra, an IL-1 receptor antagonist, which has recently showed promise in treating severe COVID-19 patients [17] [18] [19] [20] [21] [22] [23] [24] ; again, suggesting a major role of innate immune signaling in the associated pathology (Table 1) . Moreover, with regards to mitochondrial defects, the use of mitochonic acid (MA)-5 was shown to reverse several IBM-associated mitochondrial defects [25] . This review aims to revisit the role of the glycogen synthase kinase (GSK)-3 in IBM pathology both as a mediator of inclusion body formation and as a modulator of innate immune/inflammatory signaling. 

In the past, the glycogen synthase kinase-3 was examined for its role in inclusion body myositis-associated muscle degeneration based on its known role in the formation of inclusion bodies and Abeta plaques in Alzheimer's disease, and the similarity of these inclusions in protein composition with those observed in IBM. The name glycogen synthase kinase-3 in humans refers to two kinase isoforms belonging to the CMGC family of serine/threonine kinases that are encoded on separate genes located at Ch.19q13.2 (the α-isoform; a 51-kDa protein) and Ch.3q13.3 (the β-isoform; a 47-kDa protein). Both isoforms are ubiquitously expressed at the protein level in different tissues, with the greatest expression of GSK3α being observed in the brain, lung, gastrointestinal tract, pancreas, testis, ovaries and bone marrow; while GSK3β expression is most highly expressed in the brain tissue, but is also found in a number of other tissues [59] [60] [61] . Interestingly for an enzyme closely linked to glucose metabolism, only the α-isoform is significantly observed in muscle tissue, according to the Human Protein Atlas [61] . Within the cell, GSK3α localizes to the nucleus, cytosol and mitochondria, while GSK3β localizes mainly to the nucleus, cytosol or cell membrane. The GSK3 isoforms are 98% identical but maintain significant diversity in both the amino-and carboxyl-termini. In addition, GSK3α also contains an extension of the glycine-rich sequence in the amino terminus, which likely results in the differing sub-cellular localization and substrate preferences observed between these kinases [59, 60] . GSK3α/β phosphorylate and regulate proteins involved in glucose homeostasis (AKT1, IRS2), transcription (β-catenin, C/EBPα/β, CREB, c-JUN, c-MYC, STAT), microtubule assembly (ACF7, ADD2, MAP2, TAU), apoptosis (BAX, BCL3, BCL-XL, XIAP), inflammation (IKKγ, IL1-RL1, IL-17RA, IRF1, NF-κB, SMAD, TRAF6), cell cycle (CDC25A, p21 CIP1 , p53) and translation (4E-BP, eIF2Bε, EIF6) [62] . GSK3α/β-mediated phosphorylation is dependent on a priming phosphorylation carried-out by a secondary kinase at a site four amino acids C-ter to the GSK3α/β-dependent site [59, 60] . Thus, in theory, the phosphorylation of a series of GSK3α/β-dependent sites on a substrate protein (e.g., β-catenin) would occur sequentially from C-ter to N-ter, following the initial priming phosphorylation mediated by a secondary kinase. With few exceptions, GSK3α/β-mediated phosphorylations have a negative regulatory effect on the substrate [60] .

The regulation of GSK3 kinase activity is through the phosphorylation of a key tyrosine residue in the catalytic domain (Y279 or Y216 in GSK3α or β, respectively), which may be carried-out by upstream tyrosine kinases such as FYN, SRC, the proline-rich tyrosine kinase, PYK2 and even the dual Ser/Thr and Tyr kinase MEK1, thereby enhancing GSK3 catalytic activity. In addition, as the GSK3 kinases are constitutively active at a basal level, a rare autophosphorylation at these sites has also been described [63] [64] [65] [66] . The inactivation of GSK3, in contrast, requires the phosphorylation of a serine residue within the glycine-rich region of the kinase (S21 in GSK3α and S9 in GSK3β), causing a conformational change in the protein, thus blocking access of the substrate to the active site. Phosphorylation at this site can occur via AKT1, Aurora kinase, diverse ribosomal S6 kinases (p70S6K1/2, p90RSK and RSK2), serine/threonine protein kinase (SGK)-3, protein kinase A (PKA), inhibitor kappa B kinase (IKK)-ε and various protein kinase C (PKC) isoforms (https://www. phosphosite.org/siteAction.action?id=4590 (accessed on 17 November 2021); https://www. phosphosite.org/siteAction.action?id=6534 (accessed on 17 November 2021) [60, 62, 67] ). Moreover, a number of additional phosphorylation sites have been demonstrated to be important for GSK3 regulation ( Table 2 ). 

The microtubule-associated protein TAU, the product of the mapt gene, serves the purpose of facilitating microtubule assembly, thereby linking the cytoskeletal microtubule components to the plasma membrane. At least nine different isoforms of TAU are produced through alternative splicing, with some isoforms restricted to a specific developmental stage and/or tissue [68] . The largest isoform, PNS-TAU, is expressed in the peripheral nervous system, whereas the other isoforms are found in the central nervous system, kidney and urinary tract tissues, female tissues, muscle and adipose/soft tissues. TAU is a highly modified protein that is a target of at least twelve different kinases, including GSK3α/β [68] [69] [70] [71] [72] . The analysis of the PhosphoSitePlus database indicates that while GSK3α has been shown to phosphorylate a number of TAU isoforms (isoforms 2, 5, 6 and 8), GSK3β has been demonstrated to phosphorylate isoform 8 (Table 3 ) [62, [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] . The majority of the sites phosphorylated by the GSK3 kinases lie near to or within the C-ter tubulin binding repeat (aa 560-690), with the exception of two sites phosphorylated by GSK3β (S46 and T50). In general, the phosphorylation of these residues results in the detachment of TAU from the microtubule complex and disassembly. In normal tissue development, the assembly-disassembly process is regulated through an interplay between the O-GlcNacylation, phosphorylation and dephosphorylation of these sites. As phosphorylation and O-GlcNacylation are mutually exclusive post-translational modifications on a specific site, the interplay between these modifications either leads to O-GlcNacylation with consequential microtubule assembly or phosphorylation resulting in microtubule disassembly. In multiple degenerative diseases such as AD and IBM, the loss of O-GlcNacylation has been associated with the hyperphosphorylation of TAU [68, 69] . These hyperphosphorylated TAU molecules become seeds for the development of filamentous tangles which lead to the activation of the unfolded protein response (UPR), through the stress activation of the PKR-like endoplasmic reticulum kinase, PERK, and the NLRP3 inflammasome, through the activation of the stress/inflammatory kinase PKR, resulting in enhanced IL-1β synthesis, progressive inflammation, cell death and disease ( Figure 2 ) [88] [89] [90] [91] [92] [93] [94] . Table 3 . Sites of GSK3α/β-mediated phosphorylation in TAU (MAPT).

Phosphorylation Site Ref.

GSK3β

TAU isoform 5 S184 (S501) X [74] TAU isoform 5 S195 (S512) X [74] TAU isoform 5 S198 (S515) X [74] TAU isoform 5 S199 (S516) X [74] TAU Phosphorylation sites in parenthesis are indicative of the position in the fully encoded TAU protein. Information was obtained from the PhosphoSitePlus database under the substrate page at the following https://www.phosphosite.org/substrateSearchViewAction.action?id=987&type=Protein (accessed on 17 November, 2021).; https://www.phosphosite.org/substrateSearchViewAction.action?id=988&type=Protein (accessed on 17 November, 2021). Ref. [62] . The link between GSK3, amyloid precursor protein (APP)-derived Abeta and TAU in AD has been well described [95, 96] . Interestingly, a similar scenario has been proposed in IBM. While not all muscle fibers contain fibrillary inclusions, a significant number do, making this characteristic a hallmark of the IBM pathology [2, 97, 98] . Early studies have demonstrated that the overexpression of Abeta in human skeletal muscle fibers and transgenic mice could induce GSK3β activation and the enhanced phosphorylation of TAU, leading to inclusion body myositis-like pathological outcomes, including both inclusion bodies and inflammatory infiltrates in mice [99, 100] . Of significant interest was the finding by Kitazawa et al. in a mouse model of IBM (double transgenic MCK-APP/PS1 C57BL/6 mice) that acute (single intramuscular administration) and chronic (intraperitoneal administration once per week for 12 weeks) inflammatory stimulation (lipopolysaccharide; LPS) resulted in enhanced CD8 + T lymphocyte infiltrates in the muscle tissue, increased presence of pro-inflammatory cytokines (specifically IL-1β and TNFα), increased APP expression levels, enhanced GSK3β activation and enhanced TAU phosphorylation, while enhanced Abeta expression was specific to chronic inflammation [100] . Moreover, these authors demonstrated in the C2C12 mouse myoblast cell line that the inflammatory cytokines IL-1β, IL-6 and TNFα could activate GSK3β, suggesting that IBM is likely initiated by a chronic inflammatory/cellular stress insult. Additional studies have also recently linked the altered GSK3β activity to deficits in protein degradation by the autophagosome. In contrast to the role of GSK3β in Abeta and hyperphosphorylated TAU-mediated toxicity, where the activation of GSK3 is pathological, Nicot et al. demonstrated that the lack of GSK3 catalytic activity directed toward T586 of the neighbor of BRCA1 (NBR1) caused the increased protein aggregation and stabilization of ubiquitinated proteins, and found that NBR1 phosphorylation on T586 is reduced in IBM [101] . While the authors reported that the phosphorylation of T586 had no appreciable effect on the ability of NBR1 to interact with partner proteins necessary for autophagy, such as SQSTM1, UB, LC3B and GABARAP, it did interfere with NBR1 aggregate interaction and formation and the selective autophagy of ubiquitinated proteins. Their conclusions suggest that GSK3-dependent phosphorylation at T586 may serve as a switch between selective and non-selective autophagy under normal growth conditions that would be primarily regulated by flux through the PI3K-AKT-mTOR pathway. In disease conditions such as sIBM, the lack of NBR1 T586 phosphorylation, for reasons not directly associated to the presence (or absence) of active GSK3 in the affected tissue, enhances aggregate formation, overloading the autophagic system and promoting inclusions [101] . Interestingly, while GSK3β activation was the focus of many of these early analyses, according to the Human Protein Atlas, normal human muscle tissue expresses GSK3β mRNA but not the encoded protein. In contrast, both GSK3α mRNA and the encoded protein are known to be expressed in normal human muscle tissue (https://www.proteinatlas.org/ENSG00000105723-GSK3A (accessed on 25 September 2021); https://www.proteinatlas.org/ENSG00000082701-GSK3B (accessed on 25 September 2021) [61] ). This begs the question whether the original reports of the activation of GSK3 in IBM were erroneously associated with the β-isoform when GSK3α is actually the main isoform involved, or whether the protein expression of GSK3β is induced in IBM muscle fibers. One might suggest the latter, but in the studies cited, GSK3β was also observed in control muscle biopsies. As many of these studies used antibodies and Western blotting to distinguish proteins that are 98% identical at the amino acid level, some ambiguity in the isoform detected would be expected. Additional analyses are necessary to sort out which GSK3 isoform is mainly involved.

The prior studies involving GSK3 in IBM mentioned above were aimed at defining the role of GSK3β in what was considered primarily a degenerative disorder at the time. While there is still debate as to whether to consider IBM primarily an autoinflammatory pathology, a degenerative disease or both, it is very interesting to note the similarities between IBM and Alzheimer's disease. There is a close association between Alzheimer's disease and viral infection (HIV, herpes), including recent evidence demonstrating that SARS-CoV2 patients present elevated Alzheimer's-associated markers and that SARS-CoV2 accelerated AD progression in patients; interestingly, IBM was first described as a viral-associated polymyositis [102] [103] [104] . Together, these findings might point to an initial inflammatory cause of both pathologies deriving from any number of infectious or environmental factors, most likely in the background of particular genetic features. The innate immune system is not only an organism's first line of defense against infectious agents in the environment (viruses, bacteria), but also environmental stresses (toxins, pollutants) and internal stresses resulting from inherited mutations, oxidative stress, age-related DNA and protein damage, as well as physical and mechanical stresses. The acute activation of innate immune signaling has the scope of limiting cell and tissue damage, promoting cell/tissue repair and impeding the propagation of the stress and any damaged cells and macromolecules (DNA, protein, lipids) [105] . The chronic activation of innate immune signaling, on the other hand, leads to chronic inflammation and stress, which has been shown to promote tissue damage and cell death and/or changes in the cell, including the propensity to accumulate mutations, which is likely an evolutionary backdoor to randomly achieve stress adaptation, but equally capable of resulting in disease [105, 106] . The acute activation will induce a stress/inflammatory response, which may or may not involve the activation of an acquired or adaptive immune response; while, in contrast, the chronic activation of innate immune pathways will invariantly promote the activation of an acquired cell-mediated response that can also take the form of autoimmunity [107] .

Patients with inclusion body myositis are known to present with elevated pro-inflammatoryassociated cytokines and proteins in the affected tissues. In addition, as stated above, many reports have implicated a role for elevated GSK3 activity in IBM. The involvement of GSK3 in regulating the immune response has been known for some time, and its activation status is linked to both pro-and anti-inflammatory immune signaling [108, 109] . The suppression of GSK3β expression or activity was reported to drastically reduce the TLR3-mediated production of inflammatory cytokines [110] . Likewise, GSK3β KO mice were reported to have diminished pro-inflammatory but enhanced anti-inflammatory responses in their livers [111] . Bone marrowderived macrophages from these mice showed decreased TNFα transcription and increased IL-10 synthesis upon Toll-like receptor (TLR)-4 stimulation [111] . Interestingly, the reported effects of the loss of GSK3β in these mice were partially traced to the enhanced activation of AMPK in the absence of GSK3. This is highly intriguing, as AMPK is a major regulator of the STING-mediated antiviral pathway, which is involved in the activation of interferon response factor (IRF)-3 and 7 and the induction of type I interferon (IFN) synthesis [112] .

Recent evidence suggests that much of the immunoregulatory role of GSK3 lies in its ability to influence type I IFN signaling [113] [114] [115] [116] [117] . GSK3α/β are both major regulators of the WNT/β-catenin signaling pathway [60, 118] . The activation of this pathway is controlled both through the cytoplasmic sequestering of β-catenin by AXIN and its ubiquitination by TrCP1 and subsequent proteosome-mediated degradation. The AXIN polymers and GSK3 form a β-catenin destruction complex, whereby the AXIN polymers form a scaffold for the association of β-catenin and GSK3. In turn, the phosphorylation of β-catenin by GSK3 promotes its interaction with TrCP1, facilitating its degradation. In the presence of WNT, the AXIN scaffold is destabilized and β-catenin is released from the destruction complex, finally translocating to the nucleus where it stimulates the synthesis of a number of genes, including interferon response factor (IRF)-3 [113] . Not surprisingly, the overexpression of β-catenin or the inhibition of GSK3 by LiCl was reported to suppress bovine parainfluenza virus type 3 replication [114] . During productive infection, BIV promoted the degradation of β-catenin through the GSK3β-mediated proteasome pathway, suggesting a proviral role for GSK3 in promoting productive viral infection, likely through the inhibition of IFN production. Thus, in hindsight, it is rather interesting, even though no significant improvements were reported during the 6-month pilot study, that one of the first tested therapies for sIBM was IFNβ1a.

The loss or the reduction of GSK3 is not limited to IRF3 activation and type I IFN synthesis, but also results in the reduced expression of inflammatory cytokines. Li et al. reported that miR-709, which targets the GSK3β transcript, is up-regulated following the stimulation of RAW264.7 macrophage cells with LPS. The up-regulation of miR-709 enhanced the levels of β-catenin while reducing the expression of inflammatory cytokines IL-1β, IL-6 and TNFα, all known to be up-regulated in IBM patients [119] . Li et al. did not discuss the involvement of type I IFNs in this effect, but one might expect such a scenario, as type I interferons tend to promote an anti-inflammatory environment.

The regulation of IFN synthesis is not limited only to β-catenin levels and nuclear translocation, as GSK3α/β has also been shown to directly phosphorylate the prolinelinker region of IRF3, inhibiting IRF3-dependent IFN production [117] . Moreover, Qin et al. demonstrated that the tripartite motif 9 (TRIM9) short isoform undergoes autopolyubiquitination on Lys-63, serving as a platform to link GSK3β to TANK-binding kinase 1 (TBK1) [115] . Associated with TRIM9, GSK3β was shown to enhance TBK1 oligomerization and activation in a kinase-independent manner; thus, GSK3 activity did not influence the observed effects on TBK1. This interaction is of substantial importance, as TBK1 is the central kinase which figures into IRF3 transcriptional activation. It becomes activated in response to the activation of the DNA sensor cGAS and the RNA sensors RIG-I and MDA5, through the interaction of their respective downstream effectors, STING (cGAS) and MAVS (RIG-1 and MDA5). In this study, TRIM9 expression was also observed to enhance IRF3 transcriptional activation and IFN synthesis while inhibiting the expression of the pro-inflammatory cytokines, TNFα and IL-6, which is similar to that reported in RAW264.7 cells [115, 119] .

In contrast to IRF3 and type I IFN observed following GSK3 inhibition, GSK3 activity is associated with enhanced type II IFN (IFNγ) signaling, the enhanced synthesis of other pro-inflammatory cytokines and the repression of IL-10 synthesis [120] [121] [122] [123] . Such GSK3promoted conditions are observed in IBM tissues, where low IL-10 expression and enhanced IL-1, IL-6 and IFNγ drive the generation of a pro-inflammatory environment containing inflammatory macrophages and CD8 + CTLs that promote tissue damage.

These findings seem to indicate that GSK3 has a negative influence on type I IFN production while stimulating an inflammatory state, thus making GSK3 a potential target in IBM, not only at the level of degeneration, but also of inflammation (Figure 3 ). One potential caveat of this therapeutic potential may lie in observations obtained with SARS-CoV2. Like bovine parainfluenza virus infection, GSK3 activity is associated with enhanced SARS-CoV2 infection and viral production, in part due to the GSK3-mediated phosphorylation of the SARS-CoV2 nucleocapsid (N) protein, but also likely through reducing and delaying type I IFN production, resulting in enhanced pro-inflammatory cytokine expression, as observed in patients with more severe COVID-19 [124] . In a recent commentary, Dr. Christopher Rudd suggests that the use of small molecule inhibitors (SMIs) to GSK3 for SARS-CoV2 treatment may be beneficial for two reasons: the first being the inhibition of viral replication, and the second being its immunomodulatory effects [125] . However, this immuno-modulating effect to which Dr. Rudd refers is centered on enhanced CD8 + T lymphocyte (CTL) and NK cell effector functions, two factors implicated in muscle tissue destruction in IBM, and not on the pro-inflammatory cytokine storm. That said, it is quite probable that reducing the chronic inflammatory conditions in the affected tissue can bring into check the immune cell-mediated response, a process which normally occurs during the resolution phase of the immune response. Synthesis of type I interferons requires both interferon response factor (IRF), NF-κB activation and nuclear localization, and the subsequent binding to their respective elements in the IFNα/β promoter. In the presence of active GSK3, β-catenin is phosphorylated and degraded, thus inhibiting the synthesis of IRF-3, while NF-κB activation and nuclear localization are stimulated, thus favoring the synthesis of pro-inflammatory cytokines. In addition, active GSK3 also stabilizes the IFNγ receptor (IFNγR), thus enhancing IFNγ pro-inflammatory signaling. In the absence of GSK3 activity, β-catenin is released upon stimulation, translocates to the nucleus and promotes the synthesis of IRF-3. Signaling mediated by the pattern recognition receptor (PRR) proteins (RIG-I, MDA5, cGAS) promotes IRF-3 activation and nuclear localization, while the activation of PKR results in p65 NF-κB phosphorylation, activation and nuclear translocation where active p65 NF-κB either synergizes with signaling mediated by the other PRRs to aid in the synthesis of type I IFN (GSK3 inactive) or induces the synthesis of pro-inflammatory cytokines (GSK3 active).

In the past, the role of GSK3 in IBM was assessed primarily for its role in the formation of Abeta-TAU inclusions. Recent findings now tightly link GSK3 with antiviral/innate immune signaling regulation, whereby GSK3 activity inhibits the type I IFN response but promotes pro-inflammatory signaling. This is interesting, as the role of GSK3 in pathology is often found associated with that of the innate immune/antiviral/stress response kinase PKR, which is both an inducer of type I IFNs as well as an IFN response gene known to be involved in neurodegenerative diseases (Alzheimer's disease, Huntington's chorea and Creutzfeldt-Jakob disease), muscular degenerative disease (myotonic dystrophy) and cachexia [94] . While the effects of CD8 + CTL and NK cell infiltration should be monitored, SMIs to GSK3 may offer one of the best and most cost-efficient therapies/co-therapies currently available to regulate both Figure 3 . Role of GSK3 in regulating innate immune signaling. Synthesis of type I interferons requires both interferon response factor (IRF), NF-κB activation and nuclear localization, and the subsequent binding to their respective elements in the IFNα/β promoter. In the presence of active GSK3, β-catenin is phosphorylated and degraded, thus inhibiting the synthesis of IRF-3, while NF-κB activation and nuclear localization are stimulated, thus favoring the synthesis of pro-inflammatory cytokines. In addition, active GSK3 also stabilizes the IFNγ receptor (IFNγR), thus enhancing IFNγ pro-inflammatory signaling. In the absence of GSK3 activity, β-catenin is released upon stimulation, translocates to the nucleus and promotes the synthesis of IRF-3. Signaling mediated by the pattern recognition receptor (PRR) proteins (RIG-I, MDA5, cGAS) promotes IRF-3 activation and nuclear localization, while the activation of PKR results in p65 NF-κB phosphorylation, activation and nuclear translocation where active p65 NF-κB either synergizes with signaling mediated by the other PRRs to aid in the synthesis of type I IFN (GSK3 inactive) or induces the synthesis of pro-inflammatory cytokines (GSK3 active).

In the past, the role of GSK3 in IBM was assessed primarily for its role in the formation of Abeta-TAU inclusions. Recent findings now tightly link GSK3 with antiviral/innate immune signaling regulation, whereby GSK3 activity inhibits the type I IFN response but promotes pro-inflammatory signaling. This is interesting, as the role of GSK3 in pathology is often found associated with that of the innate immune/antiviral/stress response kinase PKR, which is both an inducer of type I IFNs as well as an IFN response gene known to be involved in neurodegenerative diseases (Alzheimer's disease, Huntington's chorea and Creutzfeldt-Jakob disease), muscular degenerative disease (myotonic dystrophy) and cachexia [94] . While the effects of CD8 + CTL and NK cell infiltration should be monitored, SMIs to GSK3 may offer one of the best and most cost-efficient therapies/co-therapies currently available to regulate both inclusion body formation and apoptosis in muscle tissue as well as the chronic inflammatory signaling in IBM. Some of the more promising inhibitors might be 9-ING-41 and Tideglusib, which have FDA orphan-drug status. Both demonstrate enhanced specificity and are currently in phase trials for diverse pathologies (see Table 4 ). As with all therapeutic interventions, one must weigh the patient benefit to the adverse events associated with the therapy. In most cases, the documented adverse events associated with GSK3 inhibition have ranged from mild to severe depending on the specific compound used. The mild side-effects, such as vertigo and diarrhea, to severe sideeffects, such as hypoglycemia, have been reported, with severe hypoglycemia being one of the main adverse events resulting in phase trial failure. While the phase trials utilizing 9-ING-41 are just getting well underway, a significant amount of data concerning the tolerability of Tideglusib is available. Most treatment-associated adverse events have been categorized as mild-to-moderate and have consisted of headache, diarrhea, cough, nausea, elevated liver transaminases (GGT and ALT) and creatine and fatigue. In a 2013 pilot study, and a phase II study in 2014 reported by del Ser et al. and Lovestone, et al., respectively, these adverse events were significant enough to result in a dropout rate of more than one-third of those enrolled in the trial [126] [127] [128] . So far, most studies utilizing 9-ING- 41 and Tideglusib have been focused on Alzheimer's or cancer, although a number of studies utilizing Tideglusib have recently gotten underway to evaluate its use in amyotrophic lateral sclerosis (ALS) and myotonic dystrophy (https://clinicaltrials.gov/ct2/results? cond=&term=Tideglusib&cntry=&state=&city=&dist= (accessed on 17 November 2021)). It will be necessary to determine the dose:benefit ratio in sIBM patients to determine if dosages sufficient for therapeutic response are above or below those reported previously for adverse events. [191] [192] [193] [194] [195] [196] [197] Famotidine Steric hindrance of the binding pocket H2-receptor antagonist used to treat gastric reflux disease and peptic ulcer; has neuroprotective effects 1.44 µM [198, 199] Lithium (Li ++ ) Unknown Diabetes mellitus; bipolar disorder; Alzheimer's and other neurodegenerative diseases; neuroprotective effects, anti-inflammatory effects.

2 mM [200] [201] [202] [203] [204] Naproxen Steric hindrance of the binding pocket

Non-steroidal, anti-inflammatory; Diabetes mellitus 1.5 µM [190] Olanzapine Steric hindrance of the binding pocket

Antipsychotic used for schizophrenia, bipolar disorder and anxiety; alters glucose metabolism 91.0 nM [205] [206] [207] Zinc (Zn ++) Unknown Antidepressant; alters glucose metabolism, cardioprotective effects, neurotoxic effects 15 µM 

The authors declare no conflict of interest.

Inclusion Body Myositis

Inclusion body myositis: Clinical features and pathogenesis

Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers

Theories of the pathogenesis of inclusion body myositis

Mitochondrial DNA variants in inclusion body myositis characterized by deep sequencing

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis

Alemtuzumab to Treat Sporadic Inclusion Body Myositis. ClincalTrials.gov; US Library of Medicine

The treatment of inclusion body myositis: A retrospective review and a randomized, prospective trial of immunosuppressive therapy

Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin

Inclusion body myositis: Treatment with intravenous immunoglobulin

Inclusion body myositis: Explanation for poor response to immunosuppressive therapy

Anti-T-lymphocyte globulin treatment in inclusion body myositis: A randomized pilot study

Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study

High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study

A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM

Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo

An open label trial of anakinra to prevent respiratory failure in COVID-19

Targeting protein homeostasis in sporadic inclusion body myositis

Arimoclomol in Sporadic Inclusion Body Myositis-Open Label Extension Trial. ClincalTrials.gov; US Library of Medicine

gov; US Library of Medicine

ClincalTrials.gov; US Library of Congress

Double-Blind Placebo-Controlled Pilot Study Assessing the Safety and Tolerability of Arimoclomol in Adult with Sporadic Inclusion Body Myositis. EU Clinical Trials Register

The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): A small pilot study

gov; US Library of Medicine

Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5

A Phase 1 Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM)

Non-Randomized Trial to Investigate the Efficacy and Safety of Early Versus Delayed Start of Arimoclomol in Patients with Sporadic Inclusion Body Myositis Who have Completed the IBM4809 Trial. EU Clinical Trials Register

Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis (IBM)

Phase IIa Treatment Delayed-Start Trial of the Oral JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult Idiopathic Inflammatory Myopathy. EU Clinical Trials Register

Can Local Intramuscular Botulinum Toxin Improve Dysphagia in Patients with Myopathic Dysphagia and Constriction of the Cricoid Muscle? EU Clinical Trials Register

Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients with Sporadic Inclusion Body Myositis. EU Clincal Trials Register

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203. ClinicalTrials.gov; US National Library of Medicine

Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT

Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis (BYM338)

Cells 2021

Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis

Dose-Finding, Pivotal, Phase 2b/3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility and Additional Long-Term Safety Up to 2 Years in Patients with Sporadic Inclusion Body Myositis. EU Clinical Trials Register

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients (RESILIENT)

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): A randomised, double-blind, placebo-controlled phase 2b trial

Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis. ClinicalTrials.gov; US Nationa Library of Medicine

Treatment of sporadic inclusion body myositis with bimagrumab

Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis. ClinicalTrials.gov; US National Library of Medicine

Pilot trial of etanercept in the treatment of inclusion-body myositis

Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis

Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis

IVIg) for the Treatment of Inflammatory Myopathies. ClinicalTrials.gov; US National Library of Medicine

Li-IBM). ClinicalTrials.gov; US National Library of Medicine

IBM-NAT). ClinicalTrials.gov; US National Library of Medicine

A pilot randomized trial of oxandrolone in inclusion body myositis

Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis. ClinicalTrials.gov; US National Library of Medicine

Study of Pioglitazone in Sporadic Inclusion Body Myositis. ClinicalTrials.gov; US National Library of Medicine

Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis (RAPAMI)

Simvastatin treatment in inclusion body myositis (IBM)

Simvastatin therapy in IBM

gov; US National Library of Medicine

Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells. ClinicalTrials.gov; US National Library of Medicine

ClinicalTrials.gov; US National Library of Medicine

Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis. ClinicalTrials.gov; US National Library of Medicine

Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes

Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer

Multifaceted Roles of GSK-3 in Cancer and Autophagy-Related Diseases

Tissue-based map of the human proteome

Mutations, PTMs and recalibrations

Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event

Glycogen synthase kinase-3beta is tyrosinephosphorylated by MEK1 in human skin fibroblasts

GSK-3 as potential target for therapeutic intervention in cancer

GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction

Glycogen synthase kinase 3: A key regulator of cellular fate

Tau mis-splicing in the pathogenesis of neurodegenerative disorders

Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems

Modulation of tau phosphorylation by the kinase PKR: Implications in Alzheimer's disease

PKR involvement in Alzheimer's disease

GSK-3beta, a pivotal kinase in Alzheimer disease

Protein kinase C and calcium/calmodulin-dependent protein kinase II phosphorylate three-repeat and four-repeat tau isoforms at different rates

Grundke-Iqbal, I.; Iqbal, K. Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase

Rapid tau protein dephosphorylation and differential rephosphorylation during cardiac arrest-induced cerebral ischemia and reperfusion

The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: Implications for Alzheimer's disease

Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments

Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation

PKA modulates GSK-3beta-and cdk5-catalyzed phosphorylation of tau in site-and kinase-specific manners

Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta

Spectroscopic studies of GSK3{beta} phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E

PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta

Grundke-Iqbal, I.; Iqbal, K. Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level

Grundke-Iqbal, I.; Iqbal, K. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules

Thr175-phosphorylated tau induces pathologic fibril formation via GSK3beta-mediated phosphorylation of Thr231 in vitro

c-jun N-terminal kinase hyperphosphorylates R406W tau at the PHF-1 site during mitosis

High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation

Endoplasmic reticulum stress induces tau pathology and forms a vicious cycle: Implication in Alzheimer's disease pathogenesis

The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies

Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation

Novel role of PKR in inflammasome activation and HMGB1 release

A Starring Role in Amyloid-beta-and Tau-Driven Pathological Events in Alzheimer's Disease

PKR kinase directly regulates tau expression and Alzheimer's disease-related tau phosphorylation

Glycogen synthase kinase (GSK)-3 and the double-strand RNA-dependent kinase, PKR: When two kinases for the common good turn bad

GSK-3 is essential in the pathogenesis of Alzheimer's disease

GSK-3 and Tau: A Key Duet in Alzheimer's Disease. Cells

Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM

Inflammatory myopathies with mitochondrial pathology and protein aggregates

Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice

Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta

Phosphorylation of NBR1 by GSK3 modulates protein aggregation

Myxovirus-like structures in a case of human chronic polymyositis

COVID-19 and Alzheimer's Disease

Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment

From Chronic Inflammation to Age-Related Deterioration

PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice

NLRP3: A promising therapeutic target for autoimmune diseases

Glycogen synthase kinase 3: A point of convergence for the host inflammatory response

Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3)

Glycogen synthase kinase 3beta ubiquitination by TRAF6 regulates TLR3-mediated pro-inflammatory cytokine production

Glycogen synthase kinase 3beta promotes liver innate immune activation by restraining AMP-activated protein kinase activation

AMP-activated Kinase (AMPK) Promotes Innate Immunity and Antiviral Defense through Modulation of Stimulator of Interferon Genes (STING) Signaling

Roles of GSK-3 and beta-Catenin in Antiviral Innate Immune Sensing of Nucleic Acids

Beta-catenin inhibits bovine parainfluenza virus type 3 replication via innate immunity pathway

TRIM9 short isoform preferentially promotes DNA and RNA virus-induced production of type I interferon by recruiting GSK3beta to TBK1

Fine-Tuning of the RIG-I-Like Receptor/Interferon Regulatory Factor 3-Dependent Antiviral Innate Immune Response by the Glycogen Synthase Kinase 3/beta-Catenin Pathway

Glycogen synthase kinase 3 negatively regulates IFN regulatory factor 3 transactivation through phosphorylation at its linker region

The beta-catenin destruction complex

modulates LPS-induced inflammatory response through targeting GSK-3beta

Post-translational modification of the interferon-gamma receptor alters its stability and signaling

Glycogen synthase kinase-3 promotes the synergistic action of interferon-gamma on lipopolysaccharideinduced IL-6 production in RAW264.7 cells

IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins

IFN-gamma synergizes with LPS to induce nitric oxide biosynthesis through glycogen synthase kinase-3-inhibited IL-10

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: A pilot study

A phase II trial of tideglusib in Alzheimer's disease

GSK-3 Inhibitors and Tooth Repair: An Ethical Analysis

Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects

Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation

Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo

Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors

Inhibition of GSK3 promotes replication and survival of pancreatic beta cells

Synthetic small molecules that control stem cell fate

Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytes

9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma

Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma

Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death

4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosis

GSK-3beta inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line

Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death

Neuroprotective effects of SB-415286 on hydrogen peroxide-induced cell death in B65 rat neuroblastoma cells and neurons

Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta

Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription

Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor

Trougakos, I.P. 6-bromo-indirubin-3'-oxime (6BIO), a Glycogen synthase kinase-3beta inhibitor, activates cytoprotective cellular modules and suppresses cellular senescence-mediated biomolecular damage in human fibroblasts

GSK-3beta inhibitor 6-bromo-indirubin-3'-oxime promotes both adhesive activity and drug resistance in colorectal cancer cells

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

Indirubin-3'-monoxime, a derivative of a Chinese anti-leukemia medicine, inhibits Notch1 signaling

Gsk-3beta inhibitors mimic the cardioprotection mediated by ischemic pre-and postconditioning in hypertensive rats

New perspective on the dual functions of indirubins in cancer therapy and neuroprotection

Structural features underlying selective inhibition of GSK3beta by dibromocantharelline: Implications for rational drug design

Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models

Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent

A Marine Natural Product That Acts on Both Osteoblasts and Osteoclasts and Prevents Estrogen-Dependent Bone Loss in Mice

Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania

Grundke-Iqbal, I. Role of tau phosphorylation by glycogen synthase kinase-3beta in the regulation of organelle transport

Alsterpaullone, a Cyclin-Dependent Kinase Inhibitor, Mediated Toxicity in HeLa Cells through Apoptosis-Inducing Effect

Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma

Antitumor activity of cyclin-dependent kinase inhibitor alsterpaullone in Epstein-Barr virus-associated lymphoproliferative disorders

9-cyano-1-azapaullone (cazpaullone), a glycogen synthase kinase-3 (GSK-3) inhibitor activating pancreatic beta cell protection and replication

Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases

CDK inhibitors suppress Th17 and promote iTreg differentiation, and ameliorate experimental autoimmune encephalomyelitis in mice

Protective effects of kenpaullone on cardiomyocytes following H2O2-induced oxidative stress are attributed to inhibition of connexin 43 degradation by SGSM3

Identification of GSK3beta inhibitor kenpaullone as a temozolomide enhancer against glioblastoma

The antinociceptive effects of AR-A014418, a selective inhibitor of glycogen synthase kinase-3 beta, in mice

Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS

Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418

AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans

GSK-3 Inhibitors: Preclinical and Clinical Focus on

Evidence for a new binding mode to GSK-3: Allosteric regulation by the marine compound palinurin

Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools

Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: Implication of ERK1/2 and PPARgamma receptors

Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation

Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice

Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib

A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo

NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: Potential therapeutic role in brain disorders

Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)

First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease

Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease

Manzamines: A potential for novel cures

Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus

Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death

Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: Molecular characterization in liver and muscle

Eldar-Finkelman, H. Inhibition of glycogen synthase kinase-3 ameliorates beta-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: In vivo and in vitro studies

Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3

Eldar-Finkelman, H. Inhibition of GSK-3 ameliorates the pathogenesis of Huntington's disease

Eldar-Finkelman, H. A unique type of GSK-3 inhibitor brings new opportunities to the clinic

Naproxen and cromolyn as new glycogen synthase kinase 3beta inhibitors for amelioration of diabetes and obesity: An investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation

Curcumin Ameliorates Lead-Induced Hepatotoxicity by Suppressing Oxidative Stress and Inflammation, and Modulating Akt/GSK-3beta Signaling Pathway

Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases

Curcumin protects against regional myocardial ischemia/reperfusion injury through activation of RISK/GSK-3beta and inhibition of p38 MAPK and JNK

Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats

Curcumin-mediated neuroprotection against amyloid-beta-induced mitochondrial dysfunction involves the inhibition of GSK-3beta

Curcumin mediates presenilin-1 activity to reduce beta-amyloid production in a model of Alzheimer's Disease

Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation

Famotidine inhibits glycogen synthase kinase-3beta: An investigation by docking simulation and experimental validation

Famotidine has a neuroprotective effect on MK-801 induced toxicity via the Akt/GSK-3beta/beta-catenin signaling pathway in the SH-SY5Y cell line

Inflammation and lithium: Clues to mechanisms contributing to suicide-linked traits

An Oldie but Goodie: Lithium in the Treatment of Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms

Neuroprotective effects of lithium: What are the implications in humans with neurodegenerative disorders?

Alzheimer Precision Medicine, I. Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective

Lithium and Therapeutic Targeting of GSK-3

Olanzapine inhibits glycogen synthase kinase-3beta: An investigation by docking simulation and experimental validation

Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics

Regulation of glycogen synthase kinase-3 during bipolar mania treatment

Eldar-Finkelman, H. Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: Insight into the insulin-mimetic action of zinc

Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action

Exogenous zinc protects cardiac cells from reperfusion injury by targeting mitochondrial permeability transition pore through inactivation of glycogen synthase kinase-3beta

Role of zinc and copper ions in the pathogenetic mechanisms of Alzheimer's and Parkinson's diseases